JNJ Jun 2021 60.000 put

OPR - OPR Delayed price. Currency in USD
0.4500
0.0000 (0.00%)
At close: 10:44AM EDT
Stock chart is not supported by your current browser
Previous close0.4500
Open0.4500
Bid0.1700
Ask0.9300
Strike60.00
Expiry date2021-06-18
Day's range0.4500 - 0.4500
Contract rangeN/A
Volume5
Open interest102
  • Johnson & Johnson Gets European Approval for Ebola Vaccine
    Zacks

    Johnson & Johnson Gets European Approval for Ebola Vaccine

    J&J (JNJ) gets approval from the European Commission for Ebola vaccine.

  • Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses
    Reuters

    Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses

    Early signs of the shift came Wednesday, when positive data for one of Pfizer Inc’s COVID-19 vaccine candidates sent shares of the large U.S. drugmaker up more than 3%. Although the news had little effect on shares of Pfizer’s large rivals in the vaccine race, smaller peers Moderna Inc and Inovio Pharmaceuticals Inc, both of which have previously shown promising COVID-19 data of their own, ended down more than 4% and 25%, respectively. For the week so far, shares of bigger players in the vaccine race, such as Johnson & Johnson and Merck , have also outperformed Inovio and Moderna.

  • Will Legal Problems Bankrupt Johnson & Johnson?
    Motley Fool

    Will Legal Problems Bankrupt Johnson & Johnson?

    A flurry of legal challenges is always a good reason for investors to be wary of a company. Lawsuits related to its talc-based products and the company's role in the opioid crisis present some of the biggest risks to long-term investors. Although J&J may be able to manage those legal challenges today, that doesn't mean it always will.

  • Better Buy: Eli Lilly vs. Johnson & Johnson
    Motley Fool

    Better Buy: Eli Lilly vs. Johnson & Johnson

    As two of the largest healthcare companies in the world, both Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) have a role to play in well-balanced healthcare portfolios. With a profit margin of 23.8%, 15.1% year-over-year quarterly revenue growth, and trailing-12-month revenues of $23.1 billion, Eli Lilly exudes success.

  • This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines
    Motley Fool

    This Under-the-Radar Stock Is a Better Way to Bet on Coronavirus Vaccines

    Emergent BioSolutions has become the go-to manufacturing partner for companies looking to develop vaccines for the coronavirus.

  • J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus
    Zacks

    J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus

    Johnson & Johnson (JNJ) discontinues phase III study of Stelara (ustekinumab) in systemic lupus erythematosus.

  • J&J scraps late-stage study testing Stelara for lupus
    Reuters

    J&J scraps late-stage study testing Stelara for lupus

    Stelara, which blocks two inflammation-causing proteins IL-12 and IL-23, is one of J&J's largest revenue generators, bringing in sales of about $1.82 billion in first quarter this year. The drug is approved in the United States to treat the skin condition scaly plaque psoriasis, a type of arthritis associated with psoriasis and Crohn's disease.

  • Bayer Isn’t Out of the Roundup Woods as 30,000 Claims Remain
    Bloomberg

    Bayer Isn’t Out of the Roundup Woods as 30,000 Claims Remain

    (Bloomberg) -- While Bayer AG said it took a major step toward wrapping up litigation over its Roundup weedkiller with a settlement of almost $11 billion, the company still faces about 30,000 unresolved cancer claims that could cost billions, and lawyers are vowing even more lawsuits.“If Bayer and its investors thought the Roundup litigation was wrapped up in a nice, neat ball with this settlement, they are sadly mistaken,” said Tom Kline, a Philadelphia-based plaintiffs’ lawyer who won an $8 billion verdict against Johnson & Johnson last year over one of its anti-psychotic drugs. “We are working hard getting these cases in and ready for trial.”Roundup litigation was by far the biggest liability that the German chemical giant inherited when it acquired Monsanto for $63 billion in 2018. On Wednesday, Bayer announced settlements totaling $12.1 billion that included as much as $10.9 billion for Roundup, $820 million for toxic-chemical pollution and $400 million related to damage from a dicamba-based herbicide.But Bayer only managed agreements to end about 95,000 of the 125,000 lawsuits claiming Roundup caused cancer. The others refused to settle, and the number of cases is growing. Last week, attorney Fletch Trammell filed 13 suits on behalf of kids who developed non-Hodgkin’s lymphoma after being exposed to the weedkiller in backyards, parks and playgrounds.Read More: How Roundup Went From Bayer Asset to Burden“The settlement announcement feels like Bayer is trying to stop a gigantic problem by putting its finger in the proverbial dam,” said Jason Itkin, a Houston based lawyer who won a $70 million verdict against J&J last year. “Every day, new people are diagnosed with Roundup-induced cancer. There will be thousands and thousands of future cases because Bayer is currently still selling this dangerous product.”The company denies Roundup’s active ingredient, glyphosate, is a carcinogen, a position backed by the U.S. Environmental Protection Agency.William Dodero, Bayer’s global head of litigation, said at a press conference Wednesday he couldn’t predict how many new Roundup cases will emerge. But the Leverkusen, Germany-based company has made progress in ending its Roundup litigation, resolving all the cases set for trial and those brought by the plaintiffs’ lawyers leading the litigation, Dodero said.The settlements must still be approved by a federal judge in San Francisco who has some of the cases consolidated before him.“This litigation has been going on for four years with speculation about settlement for more than a year and plaintiff attorneys have had ample opportunity to bring forward claims,” Chris Loder, a company spokesman, said in an emailed statement. “We’ve now settled approximately 75% of claims, resolved cases with all leaders” on the plaintiffs side and “have an allowance to resolve the remaining cases.”Shareholders seemed to welcome the agreements. Bayer’s American depositary receipts climbed on the settlement news, gaining as much as as 5%. The ADRs, which represent one-quarter of a regular share, were up 15 cents to $20.54 at 5:19 p.m. in New York.The company made offers to all the holdouts and is “confident that we can bring this to a final closure in due course,” Dodero said.Too LowBut Bayer’s settlement offers were insultingly low, according to James Onder, a St. Louis lawyer who held his 24,000 cases out of the settlement.“The unsettled legal exposure for Bayer could easily exceed tens of billions of dollars as our firms and others have rejected the minuscule offers accepted by some other lawyers,” Onder said in an email. “To act as if one quarter of the Roundup cancer victims don’t exist is nothing more than a flagrant attempt by Bayer to manipulate its stock price and serves as a slap in the face” to those victims, he said.After Bayer officials refused to make “serious” settlement offers, Trammell said he filed the 13 state court cases on behalf of families who say their children developed non-Hodgkin’s lymphoma from Roundup exposure. Eleven suits were filed in St. Louis last week and the others were file in San Francisco, he said.The children range in age from five to 17, according to court filings. Most are still battling their cancers, but 13-year-old Jacob Savage of Forks, Washington, died in 2017. Bayer has been hit with at least 20 other suits involving children and Roundup, court dockets show.“I’m happy they didn’t settle with me and that I can go out and get more good cases,” said Mark Robinson, a California attorney. “These guys need a couple of more verdicts against them to start valuing the cases properly.”The company lost three damage verdicts totaling more than $191 million. While those cases are on appeal, they spurred a surge in new filings over the past year that led to a plunge in Bayer shares.Precautions taken by courts during the Covid-19 pandemic -- including suspensions of jury selection -- may make it difficult for any of the plaintiff laywers to get cases set for trial until at least next year, said Ken Feinberg, who is serving as the chief settlement mediator in the Roundup cases.“I predict all the remaining cases will settle within a few months,” Feinberg said. “People are going to want their share of this settlement.”Glenn Norton, a retired Missouri appellate judge who served as a mediator for cases in St. Louis and worked with Feinberg on national settlements, said lawyers whose cases weren’t part of Wednesday’s agreement are still “determined to get them settled, too.”Norton said “Bayer paid a little more than people thought they would” to resolve most of the Roundup cases, which shows company officials were keen to get as much of the litigation behind them as possible.The consolidated case is In re: Roundup Products Liability Litigation, MDL 2741, U.S. District Court, Northern District of California (San Francisco).(Updates comment from mediator Norton. An earlier version of this story corrected a comment by the chief mediator, Feinberg.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Vaccine makers face biggest medical manufacturing challenge in history
    Reuters

    Vaccine makers face biggest medical manufacturing challenge in history

    From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.

  • Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict
    Zacks

    Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict

    J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.

  • J&J loses bid to overturn baby powder verdict, but damages cut to $2.12 billion
    Reuters

    J&J loses bid to overturn baby powder verdict, but damages cut to $2.12 billion

    The Missouri Court of Appeals lowered the original $4.69 billion verdict from July 2018 after dismissing claims by some of the 22 women and their families who had sued. "Plaintiffs proved with convincing clarity that defendants engaged in outrageous conduct because of an evil motive or reckless indifference," the court said.

  • Johnson & Johnson drops skin-whitening creams
    Reuters

    Johnson & Johnson drops skin-whitening creams

    Johnson & Johnson has decided to stop selling skin-whitening creams popular in Asia and the Middle East, it said on Friday, after such products have come under renewed social pressure in recent weeks amid a global debate about racial inequality. Johnson & Johnson will stop selling its Clean & Clear Fairness line of products, sold in India, a spokeswoman told Reuters. It was reported earlier this month that it would drop its Neutrogena Fine Fairness line, available in Asia and the Middle East.

  • Coronavirus update: New case spikes whipsaw market; Fauci warns US may not be ready for football
    Yahoo Finance

    Coronavirus update: New case spikes whipsaw market; Fauci warns US may not be ready for football

    A resurgence of coronavirus cases in key U.S. regions is nudging nationwide numbers higher, casting doubt on state efforts to relax lockdowns.

  • Exclusive: EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal - sources
    Reuters

    Exclusive: EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal - sources

    The European Commission is in advanced talks with pharmaceuticals giant Johnson & Johnson to reserve or make an up-front purchase of its COVID-19 vaccine under development, two officials familiar with the talks told Reuters. The move would be the first arranged by the European Union executive since it was mandated by the 27 EU national governments to use an emergency fund of more than 2 billion euros ($2.3 billion) to strike deals with up to six vaccine producers. The Commission's deal with U.S. company Johnson & Johnson is "in the pipeline", a top health official from an EU member state said, asking to remain anonymous because because the talks were confidential discussions about vaccines between the EU executive and EU governments.

  • Coronavirus update: States struggle to balance reopening with creeping rise in cases
    Yahoo Finance

    Coronavirus update: States struggle to balance reopening with creeping rise in cases

    The pandemic is heaping pressure on the drug industry to meet lofty expectations surrounding effective treatments.

  • The Zacks Analyst Blog Highlights: JNJ, WMT, BAC, IBM and LMT
    Zacks

    The Zacks Analyst Blog Highlights: JNJ, WMT, BAC, IBM and LMT

    The Zacks Analyst Blog Highlights: JNJ, WMT, BAC, IBM and LMT

  • Four signs of a competitive moat at Johnson amp; Johnson (NYQ:JNJ)
    Stockopedia

    Four signs of a competitive moat at Johnson amp; Johnson (NYQ:JNJ)

    Given that widespread uncertainty in the stock market is likely to endure for the rest of 2020 and beyond, it pays to know that you're investing in high-qualit...

  • Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $141.25, moving -0.63% from the previous trading session.

  • Top Research Reports for Johnson & Johnson, Walmart & Bank of America
    Zacks

    Top Research Reports for Johnson & Johnson, Walmart & Bank of America

    Top Research Reports for Johnson & Johnson, Walmart & Bank of America

  • 3 Rock Solid Dividend Stocks That Won't Flinch if the Market Crashes Again
    Motley Fool

    3 Rock Solid Dividend Stocks That Won't Flinch if the Market Crashes Again

    In this environment, it helps to own stocks that will deliver solid results and payouts no matter what happens with the coronavirus or the stock market. In addition to being the biggest retailer in the U.S. and the world, Walmart is also the biggest grocer in the country as a majority of its sales come from food and beverage categories. With its reputation for low prices, locations spread across the U.S., and convenient online grocery pickup and delivery, Walmart became a lifeline for many Americans during the crisis.

  • Coronavirus: AstraZeneca in vaccine talks with Japan, Russia, Brazil and China
    Yahoo Finance UK

    Coronavirus: AstraZeneca in vaccine talks with Japan, Russia, Brazil and China

    Pharmaceutical giant AstraZeneca in talks with four more nations to supply potential COVID-19 vaccine

  • Coronavirus: AstraZeneca signs deal to make vaccine for Europe
    Yahoo Finance UK

    Coronavirus: AstraZeneca signs deal to make vaccine for Europe

    AstraZeneca reached an agreement with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of a COVID-19 vaccine.

  • Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain
    Zacks

    Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

    Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more